Pelthos Therapeutics Inc. (PTHS) Fair Value 2026

PTHS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.4 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-08-27, Pelthos Therapeutics Inc. (PTHS) trades at $25.00. QOC: 4.4/10. Value Trap Risk: 27/100 (LOW). 0/13 models active.

Key Facts

Ticker
PTHS
Price
$25.00
Quality Score
4.4/10
Value Trap Risk
27/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.4/10 signals weak fundamentals

What Fair Value Does Each Model Give PTHS?

0 Intrinsic Value Models vs. Current Price ($25.00)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Pelthos Therapeutics Inc. (PTHS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pelthos Therapeutics Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About PTHS?

0 of 13 models are currently active for PTHS. See which stocks rank higher →

How Does PTHS Rank in Biotechnology?

Among 620 Biotechnology stocks, PTHS ranks #469 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Pelthos Therapeutics Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating PTHS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is PTHS a Value Trap?

CirclFi's Value Trap algorithm assigns PTHS a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Pelthos Therapeutics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Pelthos Therapeutics Inc.'s fundamental quality profile registers 4.4/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PTHS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pelthos Therapeutics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NWBONorthwest Biotherapeutics, Inc.QOC 4.4JAGXJaguar Health, Inc.QOC 4.4ERNAErnexa Therapeutics Inc.QOC 4.4PMCBPharmaCyte Biotech, Inc.QOC 4.4BZYRBurzynski Research Institute, Inc.QOC 4.4TECXTectonic Therapeutic, Inc.QOC 4.4HRMYHarmony Biosciences Holdings, Inc.QOC 9.2OKUROnKure Therapeutics, Inc.QOC 5.9ACRVAcrivon Therapeutics, Inc.QOC 5.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NWBO · JAGX · ERNA · PMCB · BZYR · TECX · HRMY · OKUR · ACRV · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PTHS?

5 companies across all industries closest to PTHS’s Quality of Company score of 4.4/10.

MDAMDA Space Ltd.QOC 4.4BJDXBluejay Diagnostics, Inc.QOC 4.4LDIloanDepot, Inc.QOC 4.4CTORCitius Oncology, Inc.QOC 4.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MDA · BJDX · LDI · CTOR · NVDA

Where Does PTHS Sit in CirclFi's Biotechnology Rankings?

PTHS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Pelthos Therapeutics Inc.’s Valuation?

What is Pelthos Therapeutics Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Pelthos Therapeutics Inc. (PTHS). The Quality of Company score is 4.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PTHS overvalued or undervalued right now?

At $25.00, 0 of 0 active models suggest PTHS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Pelthos Therapeutics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.4 mean for PTHS?

Pelthos Therapeutics Inc.'s QOC of 4.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PTHS?

CirclFi analyzes PTHS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is PTHS a value trap in 2026?

Pelthos Therapeutics Inc.'s Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Pelthos Therapeutics Inc. (PTHS) a Quality of Company score of 4.4/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/PTHS/ · Methodology
Primary sources for this PTHS valuation
  • Financial statements: Pelthos Therapeutics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001919246) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PTHS as of ; valuations recomputed .